CDXS
Price
$4.49
Change
-$0.02 (-0.44%)
Updated
Jan 31, 10:36 AM (EDT)
Capitalization
363.76M
26 days until earnings call
THTX
Price
$1.49
Change
+$0.05 (+3.47%)
Updated
Jan 31, 11:36 AM (EDT)
Capitalization
72.47M
Ad is loading...

CDXS vs THTX

Header iconCDXS vs THTX Comparison
Open Charts CDXS vs THTXBanner chart's image
Codexis
Price$4.49
Change-$0.02 (-0.44%)
Volume$2.18K
Capitalization363.76M
Theratechnologies
Price$1.49
Change+$0.05 (+3.47%)
Volume$3.56K
Capitalization72.47M
CDXS vs THTX Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. THTX commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a StrongBuy and THTX is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (CDXS: $4.50 vs. THTX: $1.44)
Brand notoriety: CDXS and THTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 48% vs. THTX: 97%
Market capitalization -- CDXS: $363.76M vs. THTX: $72.47M
CDXS [@Biotechnology] is valued at $363.76M. THTX’s [@Biotechnology] market capitalization is $72.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileTHTX’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • THTX’s FA Score: 1 green, 4 red.
According to our system of comparison, THTX is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 3 TA indicator(s) are bullish while THTX’s TA Score has 3 bullish TA indicator(s).

  • CDXS’s TA Score: 3 bullish, 5 bearish.
  • THTX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both CDXS and THTX are a bad buy in the short-term.

Price Growth

CDXS (@Biotechnology) experienced а -9.64% price change this week, while THTX (@Biotechnology) price change was -16.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.08%. For the same industry, the average monthly price growth was +1.56%, and the average quarterly price growth was +5.26%.

Reported Earning Dates

CDXS is expected to report earnings on May 01, 2025.

THTX is expected to report earnings on Oct 11, 2023.

Industries' Descriptions

@Biotechnology (-1.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDXS($364M) has a higher market cap than THTX($72.5M). CDXS YTD gains are higher at: -5.660 vs. THTX (-20.442). THTX has higher annual earnings (EBITDA): 11.6M vs. CDXS (-30.09M). CDXS has more cash in the bank: 90.3M vs. THTX (38.9M). CDXS has less debt than THTX: CDXS (41.8M) vs THTX (57.8M). THTX has higher revenues than CDXS: THTX (84.3M) vs CDXS (64.4M).
CDXSTHTXCDXS / THTX
Capitalization364M72.5M502%
EBITDA-30.09M11.6M-259%
Gain YTD-5.660-20.44228%
P/E RatioN/AN/A-
Revenue64.4M84.3M76%
Total Cash90.3M38.9M232%
Total Debt41.8M57.8M72%
FUNDAMENTALS RATINGS
CDXS vs THTX: Fundamental Ratings
CDXS
THTX
OUTLOOK RATING
1..100
6572
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3949
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (53) in the Chemicals Specialty industry is somewhat better than the same rating for THTX (100) in the null industry. This means that CDXS’s stock grew somewhat faster than THTX’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as THTX (100) in the null industry. This means that CDXS’s stock grew similarly to THTX’s over the last 12 months.

CDXS's SMR Rating (98) in the Chemicals Specialty industry is in the same range as THTX (100) in the null industry. This means that CDXS’s stock grew similarly to THTX’s over the last 12 months.

CDXS's Price Growth Rating (39) in the Chemicals Specialty industry is in the same range as THTX (49) in the null industry. This means that CDXS’s stock grew similarly to THTX’s over the last 12 months.

THTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that THTX’s stock grew significantly faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSTHTX
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 29 days ago
84%
Bullish Trend 25 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Ad is loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHUKX31.340.49
+1.59%
JPMorgan Emerging Markets Equity R4
JIVCX30.100.20
+0.67%
JPMorgan U.S. Applied Data Sci Val C
MSPIX66.140.34
+0.52%
NYLI S&P 500 Index Class I
FHJMX36.86N/A
N/A
Fidelity Advisor Europe I
HNRGX28.05N/A
N/A
Hennessy Energy Transition Investor

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.67%
DNLI - CDXS
51%
Loosely correlated
+0.73%
AVIR - CDXS
45%
Loosely correlated
-0.33%
BEAM - CDXS
45%
Loosely correlated
+5.29%
AXON - CDXS
43%
Loosely correlated
+2.10%
PLRX - CDXS
43%
Loosely correlated
-0.74%
More

THTX and

Correlation & Price change

A.I.dvisor tells us that THTX and IDYA have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that THTX and IDYA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To THTX
1D Price
Change %
THTX100%
-9.32%
IDYA - THTX
27%
Poorly correlated
-0.25%
ORMP - THTX
27%
Poorly correlated
-2.22%
GNPX - THTX
27%
Poorly correlated
-1.61%
CDXS - THTX
27%
Poorly correlated
+0.67%
CSLLY - THTX
26%
Poorly correlated
+1.09%
More